prevalence of high plasmatic 3omethyldopa level in a specific population of patients with a symptomatology compatible with aadc deficiency

Conditions: Aromatic L-Amino Acid Decarboxylase Deficiency

Summary: o-methydopa (3-omd) is a metabolite of the dopaminergic pathway that accumulates in case of a default in the neurotransmitter biosynthesis due to a key enzyme deficiency: aromatic l-amino acid decarboxylase (aadc) deficiency. 3-omd is a validated biomarker specific for this aadc enzyme defect. the purpose of this study is to assess the prevalence of the elevation of 3-omd in a predominantly pediatric targeted population with symptoms compatible with aadc deficiency; that will allow us to specify the indications for this screening test according to the clinical symptoms of the patients with the aim, ultimately, of optimizing the diagnosis of aadc deficiency.

-o-methydopa (3-omd) is a metabolite of the dopaminergic pathway that accumulates in case of a default in the neurotransmitter biosynthesis due to a key enzyme deficiency: aromatic l-amino acid decarboxylase (aadc) deficiency. 3-omd is a validated biomarker specific for this aadc enzyme defect. (chen et al., 2014, chien et al., 2016, brennenstuhl et al., 2019). to date, the prevalence of the elevation of 3-omd has been studied in neonatal screening of healthy newborns and in patients with a previously proven aadc deficiency but not in a target population. (chen et al., 2014, chien et al., 2016, brennenstuhl et al., 2019, kubaski et al., 2021). the prevalence of elevated plasma 3-omd, a biomarker of cerebral monoamine neurotransmitters deficiency, has never been evaluated in a targeted population. the aadc enzyme is encoded by the ddc (dopa-decarboxylase) gene. pathogenic bi-allelic variations of the ddc gene are responsible for a dysfunction of the aadc enzyme, leading to a decrease in the synthesis of biogenic amine neurotransmitters (dopamine, serotonin). aadc deficiency is a rare recessive genetic disease, with less than 200 cases published in the literature. the clinical signs begin in childhood are varied, with a broad phenotypic spectrum, reflecting the deficiency in biogenic amine neurotransmitters: motor impairment, neurodevelopmental abnormalities (delay in acquisitions, cognitive disorders and / or disorders of social interactions), dysautonomia, epileptic seizures. however, there are no specific clinical symptoms and evoking this diagnosis is tricky (pearson et al., 2020). a confirmation of the diagnosis requires at least 2 positive tests among: (i) analysis of the profile of cerebrospinal fluid (csf) neurotransmitters by lumbar puncture (ii) enzymatic study of aadc (iii) genetic study of the ddc gene (wassenberg et al. al., 2017). the cerebrospinal fluid (csf) analysis is an invasive examination and the enzymatic study is performed in only a few laboratories. therefore, it is largely admitted that this pathology is underdiagnosed (brun et al, 2010, brennenstuhl et al, 2019, hyland et al. 2019). the purpose of this study is to assess the prevalence of the elevation of 3-omd in a predominantly pediatric targeted population with symptoms compatible with aadc deficiency; that will allow investigators to specify the indications for this screening test according to the clinical symptoms of the patients with the aim, ultimately, of optimizing the diagnosis of aadc deficiency. targeted screening of the disease via the measuring of the level of 3-omd would allow for : * an early diagnosis * an adequate and pertinent therapeutic strategy, while avoiding inappropriate treatment due to lack of diagnosis, which can go as far as targeted treatment by gene therapy * genetic counseling to families since there is a 25% risk of recurrence although the level of 3-omd is a validated and specific biomarker of aadc deficiency, the blood assay is performed in very few laboratories in europe. this assay was recently developed in the biochemistry laboratory of the montpellier university hospital (pr cristol, dr badiou).

Eligibility criteria:
inclusion criteria: 1. patient with a neurodevelopmental disorder and presenting one of the following criteria: * motor development delay * cerebral palsy * hypotonia / hypertonia * movement disorders: oculogyric crises, dystonia, hypokinesia / bradykinesia * catatonia * dysautonomia: ptosis, excessive sweating, intermittent hypothermia, nasal congestion, fluctuating blood pressure * epileptic encephalopathy * autism spectrum disorder 2. absence of cerebral structural abnormality on mri apart from corpus callosum abnormality, white matter non-specific abnormality or cerebral atrophy 3. collection of informed consent signed by both parents or legal guardians and by the child if possible or formed consent signed by adult 4. patient benefiting from a social security scheme exclusion criteria 1. patient who had already have a neurotransmitter profiling or a measure of aadc enzymatic activity 2. patient with a clearly defined anoxo-ischemic history 3. patient with issues in blood collection